Monday, March 04, 2019 11:17:42 AM
LPCN’s TLANDO is not competition at this time because it is not approved.
Lipocine has received Complete Response Letters (CRL’s) from the FDA for TLANDO both times they applied for approval. The letter last year called for data from an ambulatory blood pressure monitoring study that would provide "definitive evidence" that Tlando, a testosterone replacement therapy, offers clinically meaningful increases in blood pressure for men who have deficiencies of the hormone. Regulators also want Lipocine to confirm the reliability of testosterone and maximum serum concentration (Cmax) data connected to Tlando, and to explain why the pre-specified Cmax secondary endpoints for the drug aren't applicable here. Additionally, Lipocine must come up with stopping criteria that adequately identify patients who should discontinue Tlando treatment.
Antares’ Xyosted is a relatively painless self-administered weekly auto-injection to the abdomen as shown here:
https://www.xyosted.com/application/files/8515/4335/5813/IFU-_FINAL.pdf
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM